ReviewCancer

Knowing what’s growing: Why ductal and intraductal prostate cancer matter

See allHide authors and affiliations

Science Translational Medicine  04 Mar 2020:
Vol. 12, Issue 533, eaaz0152
DOI: 10.1126/scitranslmed.aaz0152

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, “knowing what is growing” will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.

View Full Text

Stay Connected to Science Translational Medicine